Floatz logo

HYDROMORPHON

MDS

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the MDS cohort.

Asset / SponsorPhaseRating
Solu-Cortef
Andrew E. Place, MD
Phase 3BB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BB
Equine Atg
DKMS gemeinnützige GmbH
Phase 3BB
Guadecitabine
Groupe Francophone des Myelodysplasies
Phase 2BB
Benadryl
M.D. Anderson Cancer Center
Phase 2BB

View all 47 →

Same molecule, other indications

HYDROMORPHON is also rated in:

substance-related disorderDormant
BBB
Indicative ·
74 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
72 / 100
View asset →
Analgesics, OpioidDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →